Abstract
The major stress-inducible 70 kDa heat shock (stress) protein 70 (Hsp70) is frequently overexpressed in highly aggressive tumor cells and thus might serve as a tumor-specific biomarker of aggressive disease and/or therapeutic resistance. We have previously shown that, in contrast to normal cells, tumor cells present Hsp70 on their plasma membrane. In order to elucidate the role of intracellular, membrane-bound and extracellular Hsp70 as a potential tumor biomarker in cancer, herein we describe protocols for the staining of cytosolic Hsp70 in tumor formalin-fixed paraffin-embedded (FFPE) sections from patients with glioblastoma multiforme using immunohistochemistry, for detecting the expression of plasma membrane-bound Hsp70 by a range of cancer-derived cells using multi-parametric flow cytometry using the cmHsp70.1 monoclonal antibody (mAb) and for the measurement of free and vesicular-associated Hsp70 in the circulation of patients with cancer using a unique enzyme-linked immunosorbent assay (ELISA).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Multhoff G, Botzler C, Wiesnet M, Eissner G, Issels R (1995) CD3− large granular lymphocytes recognize a heat-inducible immunogenic determinant associated with the 72-kD heat shock protein on human sarcoma cells. Blood 86:1374–1382
Multhoff G, Botzler C, Wiesnet M, Muller E, Meier T, Wilmanns W, Issels RD (1995) A stress-inducible 72-kDa heat-shock protein (HSP72) is expressed on the surface of human tumor cells, but not on normal cells. Int J Cancer 61:272–279
Stangl S, Gehrmann M, Riegger J, Kuhs K, Riederer I, Sievert W, Hube K, Mocikat R, Dressel R, Kremmer E, Pockley AG, Friedrich L, Vigh L, Skerra A, Multhoff G (2011) Targeting membrane heat-shock protein 70 (Hsp70) on tumors by cmHsp70.1 antibody. Proc Natl Acad Sci USA 108:2 733-738
Gehrmann M, Stangl S, Foulds GA, Oellinger R, Breuninger S, Rad R, Pockley AG, Multhoff G (2014) Tumor imaging and targeting potential of an hsp70-derived 14-mer peptide. PLoS One 9(8):e105344. https://doi.org/10.1371/journal.pone.0105344
Gehrmann M, Pfister K, Hutzler P, Gastpar R, Margulis B, Multhoff G (2002) Effects of antineoplastic agents on cytoplasmic and membrane-bound heat shock protein 70 (Hsp70) levels. Biol Chem 383:1715–1725
Murakami N, Kuhnel A, Schmid TE, Ilicic K, Stangl S, Braun IS, Gehrmann M, Molls M, Itami J, Multhoff G (2015) Role of membrane Hsp70 in radiation sensitivity of tumor cells. Radiat Oncol 10:149. https://doi.org/10.1186/s13014-015-0461-1
Gehrmann M, Stangl S, Kirschner A, Foulds GA, Sievert W, Doss BT, Walch A, Pockley AG, Multhoff G (2012) Immunotherapeutic targeting of membrane Hsp70-expressing tumors using recombinant human granzyme B. PLoS One 7(7):e41341. https://doi.org/10.1371/journal.pone.0041341
Pfister K, Radons J, Busch R, Tidball JG, Pfeifer M, Freitag L, Feldmann HJ, Milani V, Issels R, Multhoff G (2007) Patient survival by Hsp70 membrane phenotype: association with different routes of metastasis. Cancer 110:926–935
Stangl S, Gross C, Pockley AG, Asea AA, Multhoff G (2008) Influence of Hsp70 and HLA-E on the killing of leukemic blasts by cytokine/Hsp70 peptide-activated human natural killer (NK) cells. Cell Stress Chaperones 13(2):221–230
Gross C, Holler E, Stangl S, Dickinson A, Pockley AG, Asea AA, Mallappa N, Multhoff G (2008) An Hsp70 peptide initiates NK cell killing of leukemic blasts after stem cell transplantation. Leuk Res 32(4):527–534
Multhoff G, Botzler C, Jennen L, Schmidt J, Ellwart J, Issels R (1997) Heat shock protein 72 on tumor cells: a recognition structure for natural killer cells. J Immunol 158:4341–4350
Multhoff G, Pfister K, Gehrmann M, Hantschel M, Gross C, Hafner M, Hiddemann W (2001) A 14-mer Hsp70 peptide stimulates natural killer (NK) cell activity. Cell Stress Chaperones 6(4):337–344
Stangl S, Wortmann A, Guertler U, Multhoff G (2006) Control of metastasized pancreatic carcinomas in SCID/beige mice with human IL-2/TKD-activated NK cells. J Immunol 176:6270–6276
Shevtsov M, Pitkin E, Ischenko A, Stangl S, Khachatryan W, Galibin O, Edmond S, Lobinger D, Multhoff G (2019) Ex vivo Hsp70-activated NK cells in combination with PD-1 inhibition significantly increase overall survival in preclinical models of glioblastoma and lung cancer. Front Immunol 10:454. https://doi.org/10.3389/fimmu.2019.00454
Multhoff G, Pfister K, Botzler C, Jordan A, Scholz R, Schmetzer H, Burgstahler R, Hiddemann W (2000) Adoptive transfer of human natural killer cells in mice with severe combined immunodeficiency inhibits growth of Hsp70-expressing tumors. Int J Cancer 88:791–797
Moser C, Schmidbauer C, Gurtler U, Gross C, Gehrmann M, Thonigs G, Pfister K, Multhoff G (2002) Inhibition of tumor growth in mice with severe combined immunodeficiency is mediated by heat shock protein 70 (Hsp70)-peptide-activated, CD94 positive natural killer cells. Cell Stress Chaperones 7(4):365–373
Krause SW, Gastpar R, Andreesen R, Gross C, Ullrich H, Thonigs G, Pfister K, Multhoff G (2004) Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase I trial. Clin Cancer Res 10:3699–3707
Specht HM, Ahrens N, Blankenstein C, Duell T, Fietkau R, Gaipl US, Gunther C, Gunther S, Habl G, Hautmann H, Hautmann M, Huber RM, Molls M, Offner R, Rodel C, Rodel F, Schutz M, Combs SE, Multhoff G (2015) Heat shock protein 70 (Hsp70) peptide activated natural killer (NK) cells for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy (RCTx) - from preclinical studies to a clinical phase II trial. Front Immunol 6:162. https://doi.org/10.3389/fimmu.2015.00162
Multhoff G, Seier S, Stangl S, Sievert W, Shevtsov M, Werner C, Pockley AG, Blankenstein C, Hildebrandt M, Offner R, Ahrens N, Kokowski K, Hautmann M, Rödel C, Fietkau R, Lubgan D, Huber R, Hautmann H, Duell T, Molls M, Specht H, Haller B, Devecka M, Sauter A, Combs SE (2020) Targeted natural killer cell based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy – a randomized phase II clinical study. Clin Cancer Res 26:5368–5379
Gross C, Koelch W, Demaio A, Arispe N, Multhoff G (2003) Cell surface-bound heat shock protein 70 (Hsp70) mediates perforin-independent apoptosis by specific binding and uptake of granzyme B. J Biol Chem 278(42):41173–41181
Gehrmann M, Doss BT, Wagner M, Zettlitz KA, Kontermann RE, Foulds G, Pockley AG, Multhoff G (2011) A novel expression and purification system for the production of enzymatic and biologically active human granzyme B. J Immunol Methods 371(1–2):8–17. https://doi.org/10.1016/j.jim.2011.06.007
Milani V, Stangl S, Issels R, Gehrmann M, Wagner B, Hube K, Mayr D, Hiddemann W, Molls M, Multhoff G (2009) Anti-tumor activity of patient-derived NK cells after cell-based immunotherapy - a case report. J Transl Med 7:50. https://doi.org/10.1186/1479-5876-7-50
Bashiri Dezfouli A, Yazdi M, Pockley AG, Khosravi M, Kobold S, Wagner E, Multhoff G. (2021) NK cells armed with Chimeric Antigen Receptors (CAR): Roadblocks to successful development. Cells 10:12. https://doi.org/10.3390/cells10123390
Bashiri Dezfouli A, Yazdi M, Benmebarek MR, Schwab M, Michaelides S, Micciche A, Geerts D, Stangl S, Klapproth S, Wagner E, Kobold S, Multhoff G (2022) CAR T cells targeting membrane-bound Hsp70 on tumor cells mimic Hsp70-primed NK cells. Front Immunol 13:883694. https://doi.org/10.3389/fimmu.2022.883694
Stangl S, Gehrmann M, Dressel R, Alves F, Dullin C, Themelis G, Ntziachristos V, Staeblein E, Walch A, Winkelmann I, Multhoff G (2011) In vivo imaging of CT26 mouse tumours by using cmHsp70.1 monoclonal antibody. J Cell Mol Med 15(4):874–887
Stangl S, Themelis G, Friedrich L, Ntziachristos V, Sarantopoulos A, Molls M, Skerra A, Multhoff G (2011) Detection of irradiation-induced, membrane heat shock protein 70 (Hsp70) in mouse tumors using Hsp70 Fab fragment. Radiother Oncol 99(3):313–316
Stangl S, Varga J, Freysoldt B, Trajkovic-Arsic M, Siveke JT, Greten FR, Ntziachristos V, Multhoff G (2014) Selective in vivo imaging of syngeneic, spontaneous, and xenograft tumors using a novel tumor cell-specific hsp70 peptide-based probe. Cancer Res 74(23):6903–6912
Gehrmann MK, Kimm MA, Stangl S, Schmid TE, Noel PB, Rummeny EJ, Multhoff G (2015) Imaging of Hsp70-positive tumors with cmHsp70.1 antibody-conjugated gold nanoparticles. Int J Nanomedicine 10:5687–5700
Stangl S, Tei L, De Rose F, Reder S, Martinelli J, Sievert W, Shevtsov M, Ollinger R, Rad R, Schwaiger M, D'alessandria C, Multhoff G (2018) Preclinical evaluation of the Hsp70 peptide tracer TPP-PEG24-DFO[(89)Zr] for tumor-specific PET/CT imaging. Cancer Res 78(21):6268–6281
Gastpar R, Gehrmann M, Bausero MA, Asea A, Gross C, Schroeder JA, Multhoff G (2005) Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer Res 65(12):5238–5247
Breuninger S, Erl J, Knape C, Gunther S, Regel I, Rödel F, Gaipl US, Thorsteinsdottir J, Giannitrapani L, Dickinson AM, Multhoff G (2014) Quantitative analysis of liposomal heat shock protein 70 (Hsp70) in the blood of tumor patients using a novel lipHsp70 ELISA. J Clin Cell Immunol 5:264. https://doi.org/10.4172/2155-9899.1000264
Gunther S, Ostheimer C, Stangl S, Specht HM, Mozes P, Jesinghaus M, Vordermark D, Combs SE, Peltz F, Jung MP, Multhoff G (2015) Correlation of Hsp70 serum levels with gross tumor volume and composition of lymphocyte subpopulations in patients with squamous cell and adeno non-small cell lung cancer. Front Immunol 6:556. https://doi.org/10.3389/fimmu.2015.00556
Rothammer A, Sage EK, Werner C, Combs SE, Multhoff G (2019) Increased heat shock protein 70 (Hsp70) serum levels and low NK cell counts after radiotherapy – potential markers for predicting breast cancer recurrence? Radiat Oncol 14(1):78. https://doi.org/10.1186/s13014-019-1286-0
Werner C, Stangl S, Salvermoser L, Schwab M, Shevtsov M, Xanthopoulos A, Wang F, Dezfouli AB, Thölke D, Ostheimer C, Medenwald D, Windberg M, Bache M, Schlapschy M, Skerra A, Multhoff G (2021) Hsp70 in liquid biopsies - A tumor-specific biomarker for detection and response monitoring in cancer. Cancers (Basel) 13:3706. https://doi.org/10.3390/cancers13153706
Burton EC, Prados MD (2000) Malignant gliomas. Curr Treat Options in Oncol 1(5):459–468
Nieder C, Grosu AL, Molls M (2000) A comparison of treatment results for recurrent malignant gliomas. Cancer Treat Rev 26(6):397–409
Dazzi C, Cariello A, Giannini M, Del Duca M, Giovanis P, Fiorentini G, Leoni M, Rosti G, Turci D, Tienghi A, Vertogen B, Zumaglini F, De Giorgi U, Marangolo M (2000) A sequential chemo-radiotherapeutic treatment for patients with malignant gliomas: a phase II pilot study. Anticancer Res 20(1B):515–518
Barrié M, Couprie C, Dufour H, Figarella-Branger D, Muracciole X, Hoang-Xuan K, Braguer D, Martin PM, Peragut JC, Grisoli F, Chinot O (2005) Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme. Ann Oncol 16(7):1177–1184
Combs SE, Gutwein S, Thilmann C, Debus J, Schulz-Ertner D (2005) Reirradiation of recurrent WHO grade III astrocytomas using fractionated stereotactic radiotherapy (FSRT). Strahlenther Onkol 181(12):768–773
Combs SE, Thilmann C, Edler L, Debus J, Schulz-Ertner D (2005) Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol 23(34):8863–8869
Combs SE, Wagner J, Bischof M, Welzel T, Wagner F, Debus J, Schulz-Ertner D (2008) Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. Int J Radiat Oncol Biol Phys 70(4):987–992
Combs SE, Wagner J, Bischof M, Welzel T, Edler L, Rausch R, Wagner F, Zabel-Du Bois A, Debus J, Schulz-Ertner D (2008) Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens. Int J Radiat Oncol Biol Phys 71(4):999–1005
Frenay M, Lebrun C, Lonjon M, Bondiau PY, Chatel M (2000) Up-front chemotherapy with fotemustine (F)/cisplatin (CDDP)/etoposide (VP16) regimen in the treatment of 33 non-removable glioblastomas. Eur J Cancer 36(8):1026–1031
Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996
Stupp R, Hegi ME, Mason WP, Van Den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466
Fouchaq B, Benaroudj N, Ebel C, Ladjimi MM (1999) Oligomerization of the 17-kDa peptide-binding domain of the molecular chaperone HSC70. Eur J Biochem 259(1–2):379–384
Zhang H, Liu R, Huang W (2007) A 14-mer peptide from HSP70 protein is the critical epitope which enhances NK activity against tumor cells in vivo. Immunol Investig 36(3):233–246
Acknowledgments
Gabriele Multhoff has received funding from the Deutsche Forschungsgemeinschaft (SFB824/2; DFG INST95/980-1 FUGG, INST411/37-1 FUGG, DFG KU3500/2-1, DFG STA1520/1-1), the DFG Cluster of Excellence: Munich-Centre for Advanced Photonics (MAP), the Bundesministerium für Forschung und Technologie (BMBF Innovative Therapies, 01GU0823; Kompetenzverbund Strahlenforschung 02NUK038A), the Bundesministerium für Wirtschaft und Energie BMWi (ZF4320104AJ8, ZF4320102CS7) EU-CELLEUROPE (315963), and the German Cancer Consortium Radiation Oncology Group, Munich (DKTK-ROG). The John van Geest Cancer Research Centre is supported by funding received from the John and Lucille van Geest Foundation and the Headcase Cancer Trust. GJP was awarded grant funding from the Ollie Young Foundation and Brain Tumour Research.
Conflict of Interest Statement
AGP is CEO of multimmune GmbH; GM is the founder, former CEO, and current CSO of multimmune GmbH.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Dezfouli, A.B. et al. (2023). Immunohistochemical, Flow Cytometric, and ELISA-Based Analyses of Intracellular, Membrane-Expressed, and Extracellular Hsp70 as Cancer Biomarkers. In: Calderwood, S.K., Prince, T.L. (eds) Chaperones. Methods in Molecular Biology, vol 2693. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-3342-7_23
Download citation
DOI: https://doi.org/10.1007/978-1-0716-3342-7_23
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-3341-0
Online ISBN: 978-1-0716-3342-7
eBook Packages: Springer Protocols